111, Inc. (NASDAQ:YI - Get Free Report) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 2,000 shares, a decrease of 33.3% from the March 31st total of 3,000 shares. Currently, 0.0% of the company's stock are short sold. Based on an average daily trading volume, of 34,400 shares, the days-to-cover ratio is presently 0.1 days.
Analyst Ratings Changes
Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 111 in a research report on Thursday, April 24th.
View Our Latest Report on YI
Institutional Trading of 111
Several institutional investors have recently added to or reduced their stakes in the business. FIL Ltd acquired a new stake in shares of 111 in the 4th quarter worth about $450,000. Napean Trading & Investment Co Singapore PTE Ltd bought a new stake in shares of 111 in the 4th quarter worth approximately $245,000. Finally, JPMorgan Chase & Co. lifted its position in shares of 111 by 43,619.9% during the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company's stock valued at $191,000 after acquiring an additional 305,339 shares during the last quarter. Institutional investors own 21.32% of the company's stock.
111 Stock Down 4.4 %
Shares of 111 stock traded down $0.37 on Monday, hitting $8.03. The company's stock had a trading volume of 2,166 shares, compared to its average volume of 23,454. The firm has a fifty day moving average price of $8.36 and a 200-day moving average price of $7.39. 111 has a 52-week low of $4.15 and a 52-week high of $14.10. The company has a market capitalization of $68.67 million, a P/E ratio of -2.01 and a beta of 0.47.
111 (NASDAQ:YI - Get Free Report) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter. The firm had revenue of $527.14 million for the quarter.
About 111
(
Get Free Report)
111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.
Recommended Stories
Before you consider 111, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 111 wasn't on the list.
While 111 currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
